(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 190.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 47.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.18%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $13,107,000.On average, 5 Wall Street analysts forecast TNXP's revenue for 2026 to be $1,170,452,372, with the lowest TNXP revenue forecast at $289,020,446, and the highest TNXP revenue forecast at $2,864,466,086. On average, 4 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,592,293,531, with the lowest TNXP revenue forecast at $1,332,121,508, and the highest TNXP revenue forecast at $1,851,017,770.
In 2028, TNXP is forecast to generate $1,682,511,880 in revenue, with the lowest revenue forecast at $1,616,557,307 and the highest revenue forecast at $1,731,977,809.